Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance after debulking therapy in advanced cutaneous T-cell lymphoma
2009-011020-65Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Jan 2010; status: terminated.
02
Drugs
lenalidomide
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2009-011020-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011020-65.